From capital to traction: what new NHS routes mean for health-tech founders

Last quarter, UK biotech recorded its strongest venture investment in five years, with companies raising £2.05 billion in Q2 2026, according to the BioIndustry Association. Isomorphic Labs' £1.6 billion Series B lifted that total, but funding excluding that round still reached £498 million, almost double the same period last year.

Whilst UK biotech investment is showing renewed momentum, funding alone does not create growth. For healthcare and life sciences founders, the bigger challenge is turning capital into traction.

Investors look beyond technical promise to understand whether a company can reach customers, generate revenue and scale in what has always been a complex and hard-to-reach healthcare market.

For many ventures, the gap between clinical promise and commercial progress remains difficult to close. With new government initiatives focusing on removing adoption barriers, that landscape is beginning to change.

Why traction matters more than ever

With a thriving health-tech startup, spin-outs and early-stage venture ecosystem in the UK, there is far more competition for investment. Demonstratable traction, whilst always having been important, is becoming a critical differentiator. Showing that a solution meets and solves a real market need and has a credible path to revenue, puts proof of value alongside proof of concept in the eyes of investors.

Early adoption signals can therefore have an outsized impact on how fundable a business appears.

New routes into the NHS

One such initiative is the expansion of The sandbox model, also dubbed the 'Regulatory Airlock'. Now expanding on the 4th of September to Manchester University NHS Foundation Trust (MFT) will facilitate the testing and adoption of software or AI used as a medical device (SaMD/AIaMD) and AI in medicines development. By bringing together healthcare providers, regulators and innovators earlier in the process and with appropriate oversight and guardrails, the model aims to give innovators a clearer way to test technologies in relevant clinical and healthcare settings, and generate practical evidence on their ongoing safety, effectiveness and impact. For founders, it has the potential to make early engagement with the NHS more commercially meaningful, helping them show that their technology can work in the settings where it will be used. It will also help them to better understand the evidence required for wider use.

Wider use may be more easily found by way of another of the government's initiatives, the Innovator Passport, delivered through MedTech Compass. A key part of the government's Plan for Change and its 10 Year Health Plan, it is currently being rolled out. Once deployed, it aims to reduce repeated compliance assessments across NHS organisations, so once a technology has been successfully evaluated by one trust, it can be adopted by another without need for further regulatory burden, both on the company or NHS trust.

From funding to first sale

The resurgence in biotech investment is encouraging, but the ventures most likely to progress will be those that can convert early interest into serious customer traction. And their initiatives emerging in the health tech sector aiming to support founders with this challenge.

Whilst a strong technology proposition will always matter, commercial readiness is what helps promising innovations to move from innovative opportunity to a scalable business.

What this means for founders

The message is clear: investment interest continues to strengthen but remains selective. A strong proposition needs to be paired with a practical commercial plan that explains who will buy, why now and what evidence will support adoption.

For founders, the combined effect is an improving investment landscape, but where commercial evidence carries more weight. Investors are returning selectively, and alongside technical merit they are asking a sharper question: who will buy this, and how quickly? The implications are clear. First, an evidenced route to market is central to the investment case, so founders should treat sales and procurement strategy as seriously as their technology roadmap.

Second, as real-world evidence becomes hopefully easier to generate and one NHS assessment can potentially open doors across the system, winning a first customer should become a stronger signal of commercial validation and a better foundation for follow-on capital. Founders who understand how buyers purchase, across both public and private sectors, will be best placed to convert renewed investor interest into funding.

LYVA Labs helps founders turn investor interest into customer traction through practical support with sales strategy, procurement readiness, customer discovery and market validation.

If you are building a health-tech or life sciences innovation, get in touch to strengthen your route to market and move closer to adoption, revenue and growth.